GENOME-SCALE NGS DATA
ANALYSIS AND INTERPRETATION

Dr. Erik Zmuda becomes a member of VarSome's Advisory Board

Posted by Tomas Kucera on Nov 26, 2018 11:04:29 AM

Banner - LI 1 - Nov

HPST to distribute Saphetor’s analysis platform in the Czech Republic

Posted by Tomas Kucera on Nov 20, 2018 11:37:31 AM

hpst

VarSome Search featured on GenomeWeb!

Posted by Tomas Kucera on Aug 9, 2018 11:21:00 PM

genomeweb

Saphetor’s performance at precision FDA contest

Posted by Tomas Kucera on Oct 15, 2017 8:11:00 PM

LAUSANNE, Switzerland – Saphetor S.A. is proud to report that its entry in the recent “Precision FDA” contest, organised by the Food and Drug Administration, met with resounding success.

Saphetor partners up with Supratech

Posted by Andreas Massouras on Aug 3, 2017 8:16:00 PM

LAUSANNE, Switzerland –Saphetor SA, the Swiss precision-medicine company dedicated to advancing personalized diagnostics, announced today that it will provide its proprietary platform for analyzing next-generation DNA sequencing data to Supratech Micropath (Ahmedabad, India), a reference and diagnostic lab with significant experience in clinical next-generation (NGS) DNA sequencing.

Saphetor serves Aurigen patients to enhance discovery of therapies

Posted by Andreas Massouras on Jul 12, 2017 8:18:00 PM

LAUSANNE, Switzerland – Saphetor SA, a Swiss precision-medicine company fully dedicated to advancing personalized diagnostics based on next-generation DNA sequencing, announced today a wide-ranging, pay-per-use service agreement with Aurigen SA. Aurigen is part of the Medisupport Swiss network of diagnostic labs owned by Sonic Healthcare.

Multiple agreements with University College London

Posted by Andreas Massouras on Jun 1, 2017 8:20:00 PM

LAUSANNE, Switzerland – May 25th 2017 – Saphetor, SA, a Swiss precision medicine company dedicated to advancing personalized diagnostics based on next-generation DNA sequencing, announced today a research partnership with the Exome Consortium of University College London (UCL), led by Dr. Vincent Plagnol.

Agreement with Geneva University Hospitals

Posted by Andreas Massouras on Sep 15, 2016 8:23:00 PM

Lausanne, Switzerland – September 15, 2016 – Saphetor, the leading European company in genome-scale analysis based on next generation sequencing (NGS), announced today that it has signed an agreement with the Geneva University Hospitals (HUG) to supply its Division of Genetic Medicine, headed by Professor Stylianos E. Antonarakis, with comprehensive and accurate analysis of their NGS data. Prof. Antonarakis is also Director of the Department of Genetic Medicine and Development at the University of Geneva (UNIGE) Faculty of Medicine, Director of the iGE3 institute of Genetics and Genomics, and President of the Human Genome Organization. Under the agreement, Prof. Antonarakis’ team will apply Saphetor’s precision medicine platform for clinical use. HUG has chosen to install Saphetor’s software and data solution in-house.

Collaboration with Lausanne University Hospital

Posted by Andreas Massouras on Apr 20, 2016 8:26:00 PM

Lausanne, Switzerland – April 20, 2016 Saphetor SA, a Swiss precision medicine company working at the cutting edge of clinically meaningful genome-scale analysis based on Next Generation Sequencing (NGS), announced today that it has signed a collaboration agreement with the department of endocrinology, diabetes and metabolism of the Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois or CHUV), headed by Prof. Dr. Nelly Pitteloud. Under the agreement, Prof. Pitteloud’s department will use Saphetor’s precision medicine platform in research and clinical applications.

Saphetor raises CHF1.2 million in seed financing round

Posted by Andreas Massouras on Feb 17, 2016 8:28:00 PM

Lausanne, Switzerland – February 17, 2016 Saphetor SA, a Swiss precision medicine company working at the cutting edge of clinically meaningful genome-scale analysis based on Next Generation Sequencing (NGS), announced today that it successfully completed a CHF 1.2 million seed financing round from a group of undisclosed investors.